Literature DB >> 33907625

Comments on "Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations" by D'Amato et al.

Girolamo Adiletta1, Stefano Baglioni2, Germano Bettoncelli3, Pierluigi Bracciale4, Mario Cazzola5, Enrico M Clini6, Renato Cutrera7, Franco D'Adduzio8, Francesco de Blasio9,10, Fausto Ferraro11, Roberto Fumagalli12, Cosimo Lequaglie13, Maria Gabriella Matera14, Fabio Numis15, Paolo Palange16, Stefano Picciolo17, Alfredo Potena18, Francesco Romano19, Eugenio Sabato20, Antonio Sacchetta21, Mario Spatafora22, Francesco Stefanelli23, Carlo Zottola24.   

Abstract

Entities:  

Keywords:  COVID-19; LMWH; home therapy; steroids

Year:  2021        PMID: 33907625      PMCID: PMC8056322          DOI: 10.4081/mrm.2021.757

Source DB:  PubMed          Journal:  Multidiscip Respir Med        ISSN: 1828-695X


× No keyword cloud information.
Dear Editor, We have read with interest the letter from D’Amato et al. entitled “Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations” [1], that aimed to demonstrate the usefulness of early use of prednisone and low molecular weight heparin (LMWH), in all patients with domiciliary SARS-CoV-2 infection, as a therapeutic strategy to reduce the risk of hospital admission. We are honestly surprised to read in your journal that you have accepted for publication such findings from a study that uses a therapeutic strategy which has not been approved by regulatory organisms and reports no evidence of approval from any local Ethical Committee. Indeed, these data refer to quarantined patients with mild symptoms with no indication to hospital admission by definition. To be more specific, none of the patients received neither physical medical examination, nor underwent any radiological confirmation of a possible disease progression with lung involvement. Finally, methodological weakness in study design (lack of control group with patients treated with symptomatic drugs only) precludes any firm conclusion among that we have read through the manuscript. The letter content was echoed by a regional newspaper [2] and, as expected, immediately raised confusion and misunderstanding in the general public, mainly deriving from the discrepancies between what authors stated and what the medical communities advise nationwide. In fact, medical community (General Practitioners and even more specialists) are all following statements/ guidelines that suggest the use of steroids only in patients with evidence of pneumonia with respiratory insufficiency [3-7], and LMWH in bed-bound patients with significant cardiovascular and metabolic comorbidities [8-12]. This also implicitly asserts the absolute need of a careful objective clinical evaluation to prevent any potentially dangerous misuse or overuse of medications. We believe that in the pandemic era with several sources with misleading information, a scientific journal should not agree in helping confusion. We hope that authors would be able to specify their beliefs to eventually favor a better understanding by the non-specialized press and social media.
  9 in total

1.  Dexamethasone for COVID-19? Not so fast.

Authors:  T C Theoharides; P Conti
Journal:  J Biol Regul Homeost Agents       Date:  2020 Jul-Aug,       Impact factor: 1.711

Review 2.  COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.

Authors:  Behnood Bikdeli; Mahesh V Madhavan; David Jimenez; Taylor Chuich; Isaac Dreyfus; Elissa Driggin; Caroline Der Nigoghossian; Walter Ageno; Mohammad Madjid; Yutao Guo; Liang V Tang; Yu Hu; Jay Giri; Mary Cushman; Isabelle Quéré; Evangelos P Dimakakos; C Michael Gibson; Giuseppe Lippi; Emmanuel J Favaloro; Jawed Fareed; Joseph A Caprini; Alfonso J Tafur; John R Burton; Dominic P Francese; Elizabeth Y Wang; Anna Falanga; Claire McLintock; Beverley J Hunt; Alex C Spyropoulos; Geoffrey D Barnes; John W Eikelboom; Ido Weinberg; Sam Schulman; Marc Carrier; Gregory Piazza; Joshua A Beckman; P Gabriel Steg; Gregg W Stone; Stephan Rosenkranz; Samuel Z Goldhaber; Sahil A Parikh; Manuel Monreal; Harlan M Krumholz; Stavros V Konstantinides; Jeffrey I Weitz; Gregory Y H Lip
Journal:  J Am Coll Cardiol       Date:  2020-04-17       Impact factor: 24.094

3.  Proposal of the French Society of Vascular Medicine for the prevention, diagnosis and treatment of venous thromboembolic disease in outpatients with COVID-19.

Authors:  L Khider; S Soudet; D Laneelle; G Boge; A Bura-Rivière; J Constans; M Dadon; H Desmurs-Clavel; A Diard; A Elias; J Emmerich; J-P Galanaud; P Giordana; S Gracia; A Hamade; C Jurus; C Le Hello; A Long; U Michon-Pasturel; T Mirault; G Miserey; A Perez-Martin; G Pernod; I Quere; M Sprynger; D Stephan; D Wahl; S Zuily; G Mahe; M A Sevestre
Journal:  J Med Vasc       Date:  2020-04-27

4.  Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations.

Authors:  Gennaro D'Amato; Luca Acanfora; Lucrezia Delli Paoli; Maria D'Amato
Journal:  Multidiscip Respir Med       Date:  2021-01-18

5.  Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study.

Authors:  Pablo Monedero; Alfredo Gea; Pedro Castro; Angel M Candela-Toha; María L Hernández-Sanz; Egoitz Arruti; Jesús Villar; Carlos Ferrando
Journal:  Crit Care       Date:  2021-01-04       Impact factor: 9.097

6.  The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis.

Authors:  Zhenwei Yang; Jialong Liu; Yunjiao Zhou; Xixian Zhao; Qiu Zhao; Jing Liu
Journal:  J Infect       Date:  2020-04-10       Impact factor: 6.072

7.  Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis.

Authors:  Huan Li; Chongxiang Chen; Fang Hu; Jiaojiao Wang; Qingyu Zhao; Robert Peter Gale; Yang Liang
Journal:  Leukemia       Date:  2020-05-05       Impact factor: 11.528

8.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245

9.  Should we consider heparin prophylaxis in COVID-19 patients? a systematic review and meta-analysis.

Authors:  Mohamed Abdel-Maboud; Amr Menshawy; Ahmed Elgebaly; Eshak I Bahbah; Gehad El Ashal; Ahmed Negida
Journal:  J Thromb Thrombolysis       Date:  2020-08-20       Impact factor: 2.300

  9 in total
  1 in total

Review 1.  Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality: Time for a suitable proposal.

Authors:  Sergio Pandolfi; Salvatore Chirumbolo; Giovanni Ricevuti; Luigi Valdenassi; Geir Bjørklund; Roman Lysiuk; Monica Daniela Doşa; Larysa Lenchyk; Serafino Fazio
Journal:  Basic Clin Pharmacol Toxicol       Date:  2021-12-02       Impact factor: 3.688

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.